SYNGENE INTERNATIONAL LTD Fair Value
SYNGENE · Healthcare · Current price ₹402.1
| Method | Fair value | Status |
|---|---|---|
| Residual income | ₹92 | 6% ROE fading to 12% over ~10 yrs, on ₹115 book |
| Relative P/E | ₹490 | EPS × 64.7 peer-median P/E |
| Graham floor | ₹140 | Conservative floor: √(22.5 × EPS × book value/share) |
| Analyst target | ₹502 | Street consensus 12-month target price |
Is SYNGENE INTERNATIONAL LTD undervalued?
DocStoX estimates the fair value of SYNGENE INTERNATIONAL LTD at ₹264 per share, versus the current market price of ₹402. That puts the stock about -34.4% above our fair-value estimate, which we read as "Avoid". Our confidence in this estimate is low.
How this fair value is calculated
This estimate blends 4 independent methods: Residual income (₹92), Relative P/E (₹490), Graham floor (₹140), Analyst target (₹502). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.
Bear, base and bull scenarios
Our scenarios span ₹92 (bear) to ₹264 (base) to ₹502 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.
More on SYNGENE INTERNATIONAL LTD
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.